The Kaiser Family Foundation estimates that Aduhelm will inflict significant costs on Medicaid as it covers the Alzheimer’s treatment. In a July 13 report, the foundation claimed that with a 23.1 ...
Following CMS’s preliminary decision to limit the coverage of Biogen’s Alzehimer’s disease treatment Aduhelm, advocates are calling on the agency to broaden its coverage or risk the future of similar ...
The release by the U.S. CMS of the final national coverage determination (NCD) for Biogen Inc.’s Alzheimer disease (AD) drug, Aduhelm (aducanumab), lit speculation on the meaning for others in the ...
WASHINGTON — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results